GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Simcere Pharmaceutical Group (STU:S2P) Future 3-5Y EPS without NRI Growth Rate : 21.54 (As of May. 14, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Simcere Pharmaceutical Group Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Simcere Pharmaceutical Group's Future 3-5Y EPS without NRI Growth Rate is 21.54.

Competitive Comparison of Simcere Pharmaceutical Group's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simcere Pharmaceutical Group's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Simcere Pharmaceutical Group  (STU:S2P) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Simcere Pharmaceutical Group Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
HKSE:00512 HKSE:00867 HKSE:03933 HKSE:03320 HKSE:06185 HKSE:01558 HKSE:00570 HKSE:02005 HKSE:01681 HKSE:02186 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
02096:Hong Kong
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Website
https://www.simcere.com
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Simcere Pharmaceutical Group Headlines

No Headlines